Effect of Transcutaneous Auricular Vagus Nerve Stimulation Application on Respiratory Functions in Stroke Patients
Launched by FENERBAHCE UNIVERSITY · Jan 21, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new method called Transcutaneous Auricular Vagus Nerve Stimulation (TAVSS) to see if it can help improve breathing in patients who have had a stroke. The goal is to find out if this approach can strengthen the muscles we use for breathing and make it easier for stroke survivors to recover. The study is meant for people aged 40 to 80 who had their first stroke 1 to 3 years ago and are still experiencing difficulties with their respiratory functions.
To participate, individuals must be able to follow simple instructions and not have any other serious health issues, such as heart problems or conditions affecting their ability to communicate. Potential participants will not be able to join if they have certain infections, metal implants, or have had surgery recently. Those who join the study can expect to receive TAVSS treatment and be monitored for any changes in their breathing abilities. This trial is currently not recruiting participants, but it is an important step in exploring new ways to support stroke recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being a chronic stroke patient with an ischemic or hemorrhagic stroke diagnosis made 1-3 years ago
- • Having been diagnosed with stroke for the first time
- • Ability to understand and follow simple verbal instructions
- • Being between the ages of 40 and 80
- • No conditions affecting perioral muscles, such as facial paralysis or swallowing disorders
- • No visual, auditory, or communication problems
- • No cardiopulmonary disorders
- • No additional neurological, cardiovascular, orthopedic, or similar conditions causing balance problems
- • Mini Mental State Examination (MMSE) score ≥24
- • No surgical operations or Botox applications in the last 6 months
- • Scoring 2 or below on the Modified Ashworth Scale
- Exclusion Criteria:
- • Presence of infection, ulcer, or scar on the auricle
- • Metallic implants in the skull, hypersensitivity, injury, or inflammation inside the ear
- • Chronic pulmonary and/or cardiac diseases
- • Resting heart rate below 60 beats per minute
- • Devices such as pacemakers or cochlear implants
- • Uncontrolled hypertension
- • Chronic obstructive pulmonary disease (COPD) or asthma unrelated to stroke
- • History of surgical operation or Botox application within the last 6 months
- • Presence of aphasia, apraxia, or neglect syndrome
- • History of 2 or more strokes (SVO)
- • Comorbid conditions affecting respiratory functions (e.g., Multiple Sclerosis, Parkinson's, spinal cord injury, contractures, deformities after fractures, active upper or lower respiratory infections, etc.)
- • Lack of cooperation
About Fenerbahce University
Fenerbahçe University is a distinguished academic institution dedicated to advancing healthcare research through innovative clinical trials. Committed to fostering scientific excellence and interdisciplinary collaboration, the university aims to enhance patient outcomes and contribute to the broader medical community. With a focus on rigorous methodologies and ethical standards, Fenerbahçe University leverages its state-of-the-art facilities and expert faculty to conduct groundbreaking research that addresses critical health challenges and promotes evidence-based practices. Through its clinical trial initiatives, the university strives to translate research findings into tangible benefits for patients and society at large.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Burcu AKKURT
Study Director
Fenerbahce University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported